Sun Pharmaceutical Industries, the world’s fourth-largest specialty generic pharmaceutical company, officially marked its strategic entry into the Philippine primary care market with the unveiling of the CaRMeLin Portfolio. This comprehensive therapeutic line is dedicated to Cardiometabolic, Renal, Liver, and Alimentary care, addressing the most significant health challenges facing Filipino patients today.
The scientific launch event, themed “The Golden Hour: The Best Hour,” brought together the nation’s leading experts in internal medicine, cardiology, endocrinology, and nephrology. The milestone signals a new era of access to high-quality, internationally benchmarked specialty generics in the Philippines.
Scientific Excellence and Supply Security
The launch was anchored by a keynote from Dr. Raymond R. Townsend of the University of Pennsylvania, a global authority on hypertension. Dr. Gerry H. Tan, a renowned endocrinologist and the event’s Scientific Chair, highlighted the impact of Sun Pharma’s arrival on the local medical landscape.
“Sun Pharma’s launch sets a new benchmark in manufacturing excellence and strengthens the country’s supply security for affordable specialty generics,” said Dr. Tan. “In fields where precision and bioequivalence are non-negotiable, this is a true game-changer for Filipino patients.”
A Global Powerhouse with Local Roots
With a presence in over 100 countries and more than 45 FDA- and EMA-approved manufacturing facilities, Sun Pharma ensures that its Philippine offerings meet rigorous international safety standards.
Ms. Sharon Pablo, the first Filipina Country Head of Sun Pharma Philippines, Inc., emphasized the company’s mission: “It is our commitment to Filipino patients to provide affordable, reliable, and high-quality branded generics built on global standards. Through our mission of Reaching People, Touching Lives, we aim to make meaningful health outcomes possible for every Filipino we serve.”
Addressing Gaps in Clinical Access
The CaRMeLin Portfolio is specifically designed to meet real-world clinical needs, offering:
-
High-Quality Generics: Internationally benchmarked molecules for hypertension and diabetes.
-
Therapeutic Equivalence: Molecules poised for “first-generic” status in critical categories like liver and alimentary care.
-
Affordability: Expanding treatment options without compromising efficacy or safety.
#SunKaNa: A Movement for the Filipino Patient
The launch introduced the brand message #SunKaNa, a call to action for healthcare professionals to prioritize timely, holistic, and compassionate care. As the company accelerates further FDA approvals and prepares for nationwide availability, Sun Pharma is inviting the medical community to join a movement toward better health access and quality for more patients.
ABOUT SUN PHARMACEUTICAL INDUSTRIES LTD. Sun Pharma is the world’s fourth-largest specialty generic pharmaceutical company and the No. 1 pharmaceutical company in India and Asia. It provides high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries.
Media Inquiries: For more information regarding the CaRMeLin Portfolio and Sun Pharma’s initiatives in the Philippines, visit the official Sun Pharma website.
